Movember Tissue Microarrays

Movember Patient Derived Xenografts
GAP1-PDX Project:

TMA Description Priority
Multi-institutional collection of 98 stably transferrable Patient-Derived Prostate Cancer Xenografts (Collaboration) Suitable for target validation and model selection. Clinical information on patient donors at time of tissue collection is available.
98 PDXs available: 83 unique PDXs derived directly from patient material; 15 variants of primary PDXs. All characterized with 12 biomarkers. Enquiries to:
pshepherd@mdanderson.org
https://onlinelibrary.wiley.com/doi/10.1002/pros.23701
3
Multi-institutional collection of 19 stably transferrable Patient-Derived Prostate Cancer Xenografts (Collaboration) (In development) Suitable for target validation and model selection. Clinical information on patient donors at time of tissue collection is available.
All 19 unique PDXs derived directly from patient material. Enquiries to: P. Shepherd
email P. Shepherd
3


Movember GAP1 Unique TMAs Available Soon:

TMA Description Priority
308 Case Multi-Institutional, Untreated, Parallel Primary Cancer and Lymph Node Metastases (Collaboration) For validation of prognostic biomarkers. Includes 308 cases across 661 blocks with matched untreated prostate cancer primary radical prostatectomy specimens and untreated lymph node metastasis. 5-year follow-up data for 108 cases. 3
117 case Multi-Institutional Pre- and Post-ADT/CRPC Tissues (Collaboration) For validation of prognostic biomarkers. Includes 117 cases across 174 blocks with matched pre- and post-ADT tissue from CRPC patients. Pre-ADT specimens are biopsy, TURP or RP samples. Post-ADT are TURP or metastases. Follow-up data available. 3
83 Case Multi-Institutional Multiple Metastases From Rapid Autopsies (Collaboration) For validation of prognostic biomarkers. Includes 83 cases across 326 blocks with multiple metastases per patient plus some primaries. Autopsies performed within 24 hours. Clinical treatment data available. 3